LGLili Ge

Lili Ge

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Lili Ge has a total of 18 co-authors. Here are the top co-authors by number of shared publications:

  • Juan Xu

    Department of Gynecology, Women’s Hospital of Nanjing Medical University (Nanjing Women and Children’s Healthcare Hospital), Nanjing, China

    2 shared publications
  • Xiyi Chen

    Department of Gynecology Women's Hospital of Nanjing Medical University (Nanjing Maternity and Child Health Care Hospital) Nanjing China

    2 shared publications
  • Xuemei Jia

    Department of Gynecology Women's Hospital of Nanjing Medical University Nanjing Women and Children's Healthcare Hospital Nanjing Medical University Nanjing 210004 P. R. China

    2 shared publications
  • Yaqian Shi

    Shanxi Key Laboratory of Birth Defect and Cell Regeneration, Shanxi Medical University, Taiyuan 030001, China

    2 shared publications
  • Yu Sun

    Department of Gynecology Women's Hospital of Nanjing Medical University (Nanjing Maternity and Child Health Care Hospital) Nanjing China

    2 shared publications
  • Zhe Geng

    Department of Gynecology Women's Hospital of Nanjing Medical University (Nanjing Maternity and Child Health Care Hospital) Nanjing China

    2 shared publications

Latest Publications

  • [Analysis of clinical and genetic variation in neonatal intrahepatic cholestasis caused by citrin deficiency].

    by L L Ge, C F Chen, L Liu, X Zheng, X M Zhang, Y D Zhang, S Y Mei

    Objective: To investigate the clinical phenotype and gene variation conditions in neonatal intrahepatic cholestasis caused by citrin deficiency (NICCD), so as to provide a basis for genetic counseling and clinical diagnosis and treatment of the family. Methods: 11 cases of neonatal intrahepatic cholestasis who visited the Children's Hospital Affiliated to Zhengzhou University between February 2019 and March 2021 were selected as the study subjects. High-throughput sequencing technology was used to detect the gene variation condition in 11 neonatal patients and 100 normal control neonates. The suspicious loci and family members were verified by Sanger sequencing and QPCR technology. Results: All 11 children with NICCD had different degrees of jaundice and liver damage symptoms, combined with coagulation dysfunction and anemia (n = 7), cardiac malformation (n = 2), elevated myocardial enzymes (n = 4), hyperlipidemia (n = 1), hyperkalemia (n = 1), persistent diarrhea (n = 3), developmental delay (n = 1). A total of 10 different types of SLC25A13 gene mutations were detected in 11 cases, including three frameshift mutations, two splicing changes, two missense mutations, one intron insertion, one nonsense mutation, and one heterozygous deletion. After reviewing literature and databases, c.1878delG(p.I627Sfs*73) and exon11 deletion were novel mutations that had not been reported at home or abroad. Conclusion: The clinical features of NICCD are non-specific, and genetic testing aids in the early and accurate diagnosis of the disease, providing an important basis for clinical treatment and genetic counseling for family members. In addition, the detection of novel mutation sites has enriched the SLC25A13 gene variation spectrum.

  • IGF2BP2 promotes ovarian cancer growth and metastasis by upregulating CKAP2L protein expression in an m 6 A ‐dependent manner

    by Yaqian Shi, Xueyou Xiong, Yu Sun, Zhe Geng, Xiyi Chen, Xin Cui, Juan Lv, Lili Ge, Xuemei Jia, Juan Xu

    Ovarian cancer (OC) is the second leading cause of gynecological cancer‐related death in women worldwide. N6‐methyladenosine (m 6 A) is the most abundant internal modification in eukaryotic RNA. Human insulin‐like growth factor 2 mRNA‐binding protein 2 (IGF2BP2), an m 6 A reader, can enhance mRNA stability and promote translation by recognizing m 6 A modifications. Its tumor‐promoting effects have been demonstrated in several cancers. However, the roles of m 6 A modification and IGF2BP2 in OC remain unclear. Here, by using methylated RNA immunoprecipitation sequencing, we demonstrated that there is widespread dysregulation of m 6 A modification in OC tissues. The m 6 A modification and the mRNA and protein levels of IGF2BP2 were significantly elevated in OC. Overexpression of IGF2BP2 facilitated OC cell proliferation, migration, and invasion in vitro and accelerated tumor growth and metastasis in vivo. While IGF2BP2‐knockdown showed the opposite effect. Mechanistically, we identified cytoskeleton‐associated protein 2‐like (CKAP2L) as a target of IGF2BP2. IGF2BP2 promoted CKAP2L translation dependent on m 6 A modification, rather than affecting mRNA and protein stability. Overexpression of CKAP2L rescued the tumor‐suppressive effect of IGF2BP2 knockdown in OC cells. In conclusion, this study revealed the potential role of IGF2BP2 in tumor progression, at least partially via promoting the translation of CKAP2L in an m 6 A‐dependent manner.


  • Open Access

    Plasma circRNA microarray profiling identifies novel circRNA biomarkers for the diagnosis of ovarian cancer

    by Lili Ge, Yu Sun, Yaqian Shi, Guangquan Liu, Fang Teng, Zhe Geng, Xiyi Chen, Hanzi Xu, Juan Xu, Xuemei Jia

    Background: Circular RNA (circRNA), a class of RNA with a covalent closed circular structure that widely existed in serum and plasma, has been considered an ideal liquid biopsy marker in many diseases. In this study, we employed microarray and qRT-PCR to evaluate the potential circulating circRNAs with diagnostic efficacy in ovarian cancer. Methods: We used microarray to explore the circRNA expression profile in ovarian cancer patients’ plasma and quantitative real-time (qRT)-PCR approach to assessing the candidate circRNA’s expression. Then the receiver operating characteristic (ROC) curve was employed to analyze the diagnostic values of candidate circRNAs. The diagnostic model circCOMBO was a combination of hsa_circ_0003972 and hsa_circ_0007288 built by binary logistic regression. Then bioinformatic tools were used to predict their potential mechanisms. Results: Hsa_circ_0003972 and hsa_circ_0007288 were downregulated in ovarian cancer patients’ plasma, tissues, and cell lines, comparing with the controls. Hsa_circ_0003972 and hsa_circ_0007288 exhibited diagnostic values with the Area Under Curve (AUC) of 0.724 and 0.790, respectively. circCOMBO showed a better diagnostic utility (AUC: 0.781), while the combination of circCOMBO and carbohydrate antigen 125 (CA125) showed the highest diagnostic value (AUC: 0.923). Furthermore, the higher expression level of hsa_circ_0007288 in both plasma and ovarian cancer tissues was associated with lower lymph node metastasis potential in ovarian cancer. Conclusions: Our results revealed that hsa_circ_0003972 and hsa_circ_0007288 may serve as novel circulating biomarkers for ovarian cancer diagnosis.